Surovatamig for treating relapsed or refractory follicular lymphoma

Surovatamig is currently in development for the treatment of relapsed or refractory follicular lymphoma. Follicular lymphoma develops when the body makes abnormal white blood cells called B lymphocytes. The abnormal lymphocytes do not work properly and build up causing blockages in parts of the immune system known as lymph nodes (glands). Relapsed lymphoma means that the disease has returned after responding to treatment. Refractory lymphoma means that the disease no longer responds to a specific treatment. The exact cause of follicular lymphoma is not known, but the risk is higher in people with a weak immune system, those taking medicines that suppress immunity, or those who have had been exposed to the Epstein-Barr virus. Outcomes for patients with disease progression are poor, and existing treatments are often not well tolerated, therefore there is a need to develop new treatment options for follicular lymphoma.